Has Won Taek Choe, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,669 in general payments to Won Taek Choe, MD across 65 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Won Taek Choe, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Won Taek Choe, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Won Taek Choe, MD

Otology & Neurotology · New York, NYNPI 1790871416

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Cochlear Americas at 34.0% of the total. 2025 is the largest year on record at $493, 4.8 times the $102 reported in 2019. That places this record below the midpoint for otology & neurotology clinicians in NY, where the typical reported total is $3,153.

$1,669in general payments, 2019–2025

Across 65 payments — averaging $25.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Cochlear Americas$567
Sanofi$357
GSK$193
Medtronic$67
Novartis$58
Inspire Medical Systems, Inc.$49
plus $379 from 14 others

What the payments were for

Food & beverage$1,669100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Cochlear Americas	8	$567
Sanofi	18	$357
GSK	12	$193
Medtronic	2	$67
Novartis	3	$58
Inspire Medical Systems, Inc.	2	$49
Kaleo, Inc.	3	$44
Supernus Pharmaceuticals, Inc.	1	$43
Optinose US, Inc.	2	$40
Pfizer	2	$34
Regeneron Healthcare Solutions, Inc.	2	$32
Stryker	1	$31
Alk-abello, Inc	2	$27
Integra Lifesciences Corporation	1	$25
Hikma Pharmaceuticals USA	1	$21
Med-el Corporation	1	$19
Paratek Pharmaceuticals, Inc.	1	$17
Teva Pharmaceuticals USA, Inc.	1	$17
Smith+Nephew	1	$15
Eyevance Pharmaceuticals LLC	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Baha$242
Nucleus$136
Osia$136
Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode$106
OSIA OSI300 IMPLANT$106

How this compares

$1,669 in reported general payments places this provider in the 30th percentile of 26 otology & neurotology providers in New York.

See all otology & neurotology providers in New York →

Medicare billing

Part B allowed, 2024

$251,222

Medicare patients

639

Services billed

2,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tobramycin-DexamethasoneTobramycin/Dexamethasone	207	$15,581
Nortriptyline Hcl	144	$3,223
Fluticasone Propionate	151	$2,492
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid	228	$2,245
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth	17	$2,180
Propranolol Hcl ErPropranolol Hcl	31	$1,186
Verapamil ErVerapamil Hcl	34	$801
Verapamil Hcl	51	$790
Acetazolamide	19	$750
Azelastine Hcl	27	$700
Clotrimazole	23	$622
Ofloxacin	28	$456
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	24	$445
Methylprednisolone	50	$406
Tobramycin	35	$273

Paid to pharmacies, not to this prescriber.

Other otology & neurotology in New York

John RolandNew York$86K
Sean McMenomeyNew York$27K
Daniel JethanamestNew York$17K
Zachary SchwamNew York$15K
David FriedmannNew York$11K
George AlexiadesNew York$8K
Sujana ChandrasekharNew York$5K
Eric SmouhaNew York$5K
Darius KohanNew York$3K
Neil SperlingNew York$2K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →